Loading WW detail
Loading ticker data...
Loading WW detail
WW International, Inc. provides weight management products and services worldwide.
The company operates in four segments: North America, Continental Europe, United Kingdom, and Other. It offers a range of nutritional, activity, behavioral, and lifestyle tools and approaches products and services. The company also provides various digital subscription products to wellness and weight management business, which provide interactive and personalized resources that allow users to follow its weight management program through its app and Web-based products, including personal coaching and digital products; and allows members to inspire and support each other by sharing their experiences with other people on weight management and wellness journeys. In addition, it offers various consumer products, including bars, snacks, cookbooks, kitchen tools, and other products. Further, the company licenses its trademarks and other intellectual property in food, beverages, and other relevant consumer products and services, as well as provides publishing services. It offers products through e-commerce platforms and through partners. The company was formerly known as Weight Watchers International, Inc. and changed its name to WW International, Inc. in September 2019.
WW International, Inc. was founded in 1961 and is headquartered in New York, New York.
Chart data unavailable
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) ("Weight Watchers"), the global leader in science-backed weight management, announced that it is now offering access to Eli Lilly and Company's newly FDA-approved oral GLP-1, Foundayo (orforglipron) through its Medoffering and affiliated medical groups.
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced the following updates to the composition of its Board of Directors' standing committees following the appointments of Lisa Gavales and Sue Gove as independent directors: Audit Committee: Gene Davis (Chair), Sue Gove, Carney Hawks and Nikolaj Sjoqvist; Compensation and Benefits Committee: Carney Hawks (Chair), Gene Davis and Lisa Gavales; Nominating and Corporate Governance Committee: Nikolaj Sjoqvist (Chair), Gene Davis and Sue Gove; and Strategy and Finance Committee: Gene Davis (Chair), Lisa Gavales, Carney Hawks, Mike Mason and Nikolaj Sjoqvist. Office of the CEO Update As previously announced, the Board established a Transition Committee to oversee the Office of the CEO, which comprises Felicia DellaFortuna, the Company's Chief Financial Officer, and Jon Volkmann, the Company's Chief Operations Officer.
New, Independent Directors Bring Deep Consumer, Digital and Turnaround Expertise to Support Strategic Transformation New, Independent Directors Bring Deep Consumer, Digital and Turnaround Expertise to Support Strategic Transformation
Office of the CEO Established to Oversee Business Operations Board Forms Transition Committee and Commences CEO Search NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced leadership and governance changes, including the establishment of an Office of the CEO and the formation of a new Transition Committee of the Board of Directors (“the Board”). These actions follow Tara Comonte's departure from the Company, effective March 31, 2026.
Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers' integrated care platform Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers' integrated care platform
WW International, Inc. (WGHTQ) Q4 2025 Earnings Call Transcript
WW International (NASDAQ:WW), the global weight management company formerly known as Weight Watchers, released its fourth quarter and full-year 2025 financial results, showing stronger-than-expected earnings despite a year-over-year decline in total revenue. The company's shares surged more than 12% following the report, trading just shy of $24 on Monday morning.
2025 Total Revenue and Adjusted EBITDA 1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with continued growth in first quarter 2026 Fourth Quarter Total Revenue of $163 million; Clinical Subscription Revenue of $27 million, up 32% year-over-year Fourth Quarter Net Loss of $6 million; Net Loss Margin of 3.6%; Adjusted EBITDA 1 of $18 million and Adjusted EBITDA Margin 1 of 11.1% Provides First Quarter 2026 End of Period Subscriber Estimates and Full Year 2026 Financial Guidance NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the fourth quarter and full year fiscal 2025 ended December 31, 2025 2 in this Earnings Press Release and a Shareholder Letter posted on the Company's Corporate Website . “Our industry is undergoing a profound transformation driven by GLP-1 medications, and Weight Watchers is evolving alongside it,” said Tara Comonte, CEO of Weight Watchers.
WW International, Inc. (NASDAQ: WW - Get Free Report) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 1,593,503 shares, a growth of 28.9% from the January 29th total of 1,236,706 shares. Based on an average daily trading volume, of 328,331 shares, the days-to-cover
NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Monday, March 16, 2026.
The new partnership combines Weight Watchers' scientifically-backed medical and behavioral expertise with PVOLVE's clinically-studied method to support members at every age and stage of life The new partnership combines Weight Watchers' scientifically-backed medical and behavioral expertise with PVOLVE's clinically-studied method to support members at every age and stage of life
A NovoCare® Recognized Care Provider, Weight Watchers' new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone A NovoCare® Recognized Care Provider, Weight Watchers' new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone
WW International, Inc. (NASDAQ: WW - Get Free Report) crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $27.60 and traded as high as $29.40. WW International shares last traded at $28.44, with a volume of 251,911 shares changing hands. Analyst Upgrades and Downgrades WW has
A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last
